CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

5/6/24 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRMD alert in real time by email

BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2024, before the market opens on Thursday, May 9, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

*Thursday, May 9*^th @ 8:30am ET
Domestic:	1-888-886-7786
International:	1-416-764-8658
Conference ID:	32817785
Webcast:	Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^®, which was approved by the FDA on November 15, 2023 and launched in inpatient settings in April 2024. CorMedix anticipates the commercial launch of DefenCath in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors

[email protected]

(617) 430-7576

Get the next $CRMD alert in real time by email

Date	Price Target	Rating	Analyst
8/26/2024	$13.00	Buy	Rodman & Renshaw
8/10/2023	$6.00	Outperform	RBC Capital Mkts

CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

Chat with this insight

Recent Analyst Ratings for $CRMD

$CRMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP Hurlburt Elizabeth exercised 140,027 shares at a strike of $4.48 and sold $1,565,670 worth of shares (140,027 units at $11.18), increasing direct ownership by 308% to 185,424 units (SEC Form 4)

Todisco Joseph covered exercise/tax liability with 26,982 shares, decreasing direct ownership by 8% to 325,857 units (SEC Form 4)

SEC Form 4 filed by Lefkowitz Steven W

$CRMD Press Releases

Fastest customizable press release news feed in the world

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

$CRMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

SEC Form SC 13G filed by CorMedix Inc.

$CRMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Cormedix with a new price target

RBC Capital Mkts initiated coverage on Cormedix with a new price target

Needham reiterated coverage on Cormedix with a new price target

$CRMD SEC Filings

SEC Form 10-Q filed by CorMedix Inc.

CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by CorMedix Inc.

$CRMD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

November 17, 2023 - FDA Roundup: November 17, 2023

FDA Approval for DEFENCATH issued to CORMEDIX INC

$CRMD Financials

Live finance-specific insights

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

$CRMD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

Mistry Erin bought $4,000 worth of shares (1,000 units at $4.00), increasing direct ownership by 26% to 4,900 units (SEC Form 4)

$CRMD Market Insights

Live Market Insights

$CRMD Leadership Updates

Live Leadership Updates

Needham Reiterates Buy on Cormedix, Maintains $10 Price Target

CorMedix Receives FDA Support for Expanded Indication of DefenCath in Adult TPN Patients; Plans to Submit Clinical Protocol in Q3 2024 and Initiate Program by Year-End

CorMedix Announces CMS Grants Pass-Through Status For DefenCath Under Hospital Outpatient Prospective Payment System (OPPS)

CorMedix Inc. Announces Appointment of Chief Legal Officer

CorMedix Inc. Announces Partnership With The Leapfrog Group

Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

Recent Analyst Ratings for
$CRMD

$CRMD
Insider Trading

$CRMD
Press Releases

$CRMD
Large Ownership Changes

$CRMD
Analyst Ratings

$CRMD
SEC Filings

$CRMD
FDA approvals

$CRMD
Financials

$CRMD
Insider Purchases

$CRMD
Market Insights

$CRMD
Leadership Updates